We are excited to announce that Rarity Bioscience is a Gold Sponsor at the upcoming ESCCA 2024 Conference, reaffirming our commitment to advancing scientific cell analysis. The European Society for Clinical Cell Analysis (ESCCA) Conference is a leading event that unites top experts and researchers worldwide to discuss cutting-edge developments in flow cytometry and related technologies.
The superRCA® pioneer program: superRCA NPM1 Mutation Kit RUO
As part of our participation, Rarity Bioscience is thrilled to pre-launch our highly anticipated superRCA NPM1 Mutation Kit RUO at ESCCA 2024. This innovative assay platform brings ultra-sensitive mutation detection to flow cytometry, offering unparalleled precision and versatility for a wider range of translational research applications, including minimal residual disease (MRD) detection. The superRCA® assays convert nucleic acid sequences into large fluorescent particles, enabling direct measurement of the ratio between wild-type and mutated sequences, with a sensitivity that surpasses conventional technologies.
Celebrating Last Year's Success
Rarity Bioscience made a powerful impact at last year’s ESCCA Conference, where Dr. Lei Chen, the CTO and co-founder of Rarity Bioscience, was honored with the Award for Best Oral Presentation. The presentation was recognized for its originality, scientific value, and significant contribution to the field. We are confident that our participation this year as a Gold Sponsor will once again demonstrate our commitment to delivering high-impact innovations!
Visit Us at ESCCA 2024 – Booth #G1
Conference attendees are invited to visit our booth, where we will showcase the new superRCA NPM1 Mutation Kit RUO and other recent developments from our company. Our team will be available to discuss how superRCA® technology can revolutionize molecular mutation detection in your research.
📍 Booth #G1
📧 Feri Shahin, feri.shahin@raritybioscience.com
Go with the flow – Add Molecular!
